Association Study of Transforming Growth Factor Beta 1+29 T/C exon 1 Polymorphism in Breast Cancer Patients from North Indian Population

被引:0
作者
Pal, Ranjana [1 ,2 ]
Dutta, Siddhartha [2 ,3 ,4 ]
机构
[1] Presidency Univ, Dept Life Sci, 86-1 Coll St, Kolkata 700073, West Bengal, India
[2] Jawaharlal Nehru Univ, Dept Life Sci, New Delhi, India
[3] Univ Engn & Management, Dept Biotechnol, Kolkata, West Bengal, India
[4] Sister Nivedita Univ, Dept Microbiol & Biotechnol, Kolkata, West Bengal, India
关键词
TGFB1; +29T; C polymorphism; Breast cancer; Apoptosis; TGF-BETA; GENETIC POLYMORPHISMS; INDUCED APOPTOSIS; IFN-GAMMA; DUAL ROLE; TGF-BETA-1; CELLS; TRAIL; GROWTH-FACTOR-BETA-1; ACTIVATION;
D O I
10.1007/s12010-023-04438-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: TGFB1 cytokine is involved in normal mammary epithelial development as well as in breast tumorigenesis. It has role in both breast tumor suppression and progression. TGFB1 gene has several single nucleotide polymorphisms (SNPs) many of which modulate the activity of TGFB1. Our aim in this study was to analyze TGFB1 + 29 polymorphism in breast cancer individuals from North Indian population. Methods: TGFB1 + 29 T/C polymorphism was analyzed using Sanger sequencing in 285 breast cancer patients and age matched 363 healthy controls from North Indian population. Next, transcript expression of 13 apoptotic genes, TRAIL, DR4, DR5, DcR1, DcR2, Bcl2, cytochrome c, Casp8L, Casp8, FlipS, FlipL, Casp3s and Casp3 were carried out in 77 breast tumor tissues obtained from 77 individuals. Results: TGFB1 + 29 CC genotype provided protection against the development of breast cancer (P = 0.012). This was mainly attributable to higher age group (> 45 years) women (P = 0.016). Individuals having CC protector genotype showed significantly higher expression of TGFB1 transcript compared to the TT and TC risk genotypes (P = 0.044). Furthermore, we observed that TGFB1 + 29 CC genotype showed increased TRAIL mediated apoptosis via the extrinsic pathway in breast tumor patients with age greater than 45 years (P = 0.027). Conclusion: TGFB1 + 29 homozygous mutant CC genotype is related to protection against breast cancer in North Indian women population greater than 45 years of age.
引用
收藏
页码:3671 / 3680
页数:10
相关论文
共 50 条
  • [21] c.29C>T polymorphism in the transforming growth factor-β1 (TGFB1) gene correlates with increased risk of urinary bladder cancer
    Gautam, Kirti Amresh
    Pooja, Singh
    Sankhwar, Satya Narayan
    Sankhwar, Pushp Lata
    Goel, Apul
    Rajender, Singh
    CYTOKINE, 2015, 75 (02) : 344 - 348
  • [22] Transforming growth factor beta 1 serum levels in patients with preinvasive and invasive lesions of the breast
    Lebrecht, A
    Grimm, C
    Euller, G
    Ludwig, E
    Ulbrich, E
    Lantzsch, T
    Hefler, L
    Koelbl, H
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2004, 19 (03) : 236 - 239
  • [23] Transforming growth factor β1 T868C gene polymorphism is associated with cerebral infarction in Japanese patients with type 2 diabetes
    Katakami, N.
    Kaneto, H.
    Osonoi, T.
    Kawai, K.
    Ishibashi, F.
    Imamura, K.
    Maegawa, H.
    Kashiwagi, A.
    Watada, H.
    Kawamori, R.
    Shimomura, I.
    Yamasaki, Y.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 94 (03) : E57 - E60
  • [24] Association between transforming growth factor-β1 expression and the clinical features of triple negative breast cancer
    Ding, Ming-Jian
    Su, Ke
    Cui, Guo-Zhong
    Yang, Wen-Hua
    Chen, Liang
    Yang, Meng
    Liu, Yan-Qing
    Dai, Dian-Lu
    ONCOLOGY LETTERS, 2016, 11 (06) : 4040 - 4044
  • [25] Role of transforming growth factor-β1 in triple negative breast cancer patients
    Zhang, Mingxia
    Wu, Jiannan
    Mao, Kai
    Deng, Heran
    Yang, Yaping
    Zhou, Enxiang
    Liu, Jieqiong
    INTERNATIONAL JOURNAL OF SURGERY, 2017, 45 : 72 - 76
  • [26] Transforming growth factor-β1 gene promoter-509C/T polymorphism in association with expression affects colorectal cancer development and depends on gender
    Stanilova, Spaska
    Stanilov, Noyko
    Julianov, Alexander
    Manolova, Irena
    Miteva, Lyuba
    PLOS ONE, 2018, 13 (08):
  • [27] Plasma transforming growth factor β1 in breast cancer patients treated with CMF chemotherapy
    Kajdaniuk, D
    Marek, B
    Swietochowska, E
    Ostrowska, Z
    Glogowska-Szelag, J
    Kos-Kudla, B
    Ciesielska-Kopacz, N
    Wielkoszyski, T
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2000, 25 (04) : 291 - 294
  • [28] Association of transforming growth factor-β1 T869C gene polymorphism with diabetic nephropathy risk
    Zhou, Tian-Biao
    Jiang, Zong-Pei
    Qin, Yuan-Han
    Drummen, Gregor P. C.
    NEPHROLOGY, 2014, 19 (02) : 107 - 115
  • [29] Transforming Growth Factor Beta-1 C-509T Polymorphism and Cancer Risk: A Meta-analysis of 55 Case-control Studies
    Liu, Yang
    Lin, Xian-Fan
    Lin, Chun-Jing
    Jin, Si-Si
    Wu, Jin-Ming
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (09) : 4683 - 4688
  • [30] The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk
    Krippl, P
    Langsenlehner, U
    Renner, W
    Yazdani-Biuki, B
    Wolf, G
    Wascher, TC
    Paulweber, B
    Bahadori, B
    Samonigg, H
    CANCER LETTERS, 2003, 201 (02) : 181 - 184